Posts

Provention Bio entered a co-promotion agreement with Sanofi Thursday ahead of the possible November approval of Type 1 diabetes drug teplizumab.

Regeneron Pharmaceuticals Inc. said on Thursday the company would buy the global rights to the cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.